Juan M Hincapie-Castillo, Pharm.D., M.S., Ph.D.
Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 273-5526
Business Email:
j.hincapie@ufl.edu
About Juan M Hincapie-Castillo
Juan M. Hincapie-Castillo, Pharm.D, M.S., Ph.D., joined the Department of Pharmaceutical Outcomes and Policy as an assistant professor in 2019. He is a graduate from the University of Florida College of Pharmacy where he received the degrees of Doctor of Pharmacy (2013), Master of Science in Pharmaceutical Sciences (2017), and Ph.D. with a concentration in pharmacoepidemiology (2019). He is the recipient of the 2020 New Investigator Award from the American Association of Colleges of Pharmacy and the 2020 Emerging Leader Award from the International Society for Pharmacoepidemiology (ISPE). His research interests include the study of drug utilization and safety in the area of pain management, the evaluation of the effects of State and Federal laws on patient outcomes (legal epidemiology), and the assessment of patient safety and quality for inpatient pain management.
Juan is the current chair of the Latin American Regional Interest Group for ISPE, and he is a consultant for the FDA’s Drug Safety and Risk Management Advisory Committee (DSaRM). In 2021, he was appointed as a Research Fellow for the Center for Public Health Law Research (CPHLR) at Temple University. He currently serves in the Science and Policy Advisory Board for the National Pain Advocacy Center.
Accomplishments
Research Fellow
2021
·
Center for Public Health Law Research – Temple University
Emerging Leader Award
2020
·
International Society for Pharmacoepidemiology
Faculty Role Model Award
2020
·
Comprehensive Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program
Keynote Speaker – Doctoral & Master’s Commencement Summer 2020
2020
·
University of Florida College of Pharmacy
New Investigator Award
2020
·
American Association of Colleges of Pharmacy
Outstanding Reviewer
2020
·
Journal of the American Pharmacists Association
Best Reviewer Recognition in 2018
2019
·
Pharmacoepidemiology and Drug Safety (Journal)
Research Profile
Drug utilization and safety in pain management, evaluation of the effects of State and Federal laws on patient outcomes (legal epidemiology), and assessment of patient safety and quality for inpatient pain management.
Open Researcher and Contributor ID (ORCID)
0000-0002-6945-2713
Areas of Interest
- Legal Epidemiology
- Pain Management
- Pharmacoepidemiology
- health services research
Publications
2021
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.
Medical cannabis and cannabinoids.
4(1):21-42
[DOI] 10.1159/000515069.
[PMID] 34676348.
2021
A survey assessment of clinician perceptions of opioid supply and monitoring requirement policy changes.
Journal of opioid management.
17(4):337-342
[DOI] 10.5055/jom.2021.0666.
[PMID] 34533828.
2021
Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends.
JAMA internal medicine.
181(6):808-816
[DOI] 10.1001/jamainternmed.2021.1154.
[PMID] 33871571.
2021
Changes in Prescribing by Provider Type Following a State Prescription Opioid Restriction Law.
Journal of general internal medicine.
[DOI] 10.1007/s11606-021-06966-4.
[PMID] 34236602.
2021
Changes in Quantity of Opioids Dispensed following Florida’s Restriction Law for Acute Pain Prescriptions
Pain Medicine.
[DOI] 10.1093/pm/pnab017.
[PMID] 33502536.
2021
Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida’s Acute Pain Opioid Restriction Law.
Journal of managed care & specialty pharmacy.
27(6):779-784
[DOI] 10.18553/jmcp.2021.27.6.779.
[PMID] 34057389.
2021
Chronic Opioid Therapy Utilization Following an Acute Pain Prescription Supply Restriction Law: An Interrupted Time Series Analysis.
Pain physician.
24(6):417-424
[PMID] 34554682.
View on:
PubMed
2021
Chronic Opioid Therapy: A Scoping Literature Review on Evolving Clinical and Scientific Definitions
The Journal of Pain.
22(3):246-262
[DOI] 10.1016/j.jpain.2020.09.002.
View on:
Publisher’s Site
2021
Co-utilization of opioids and nonbenzodiazepine hypnotic drugs in U.S. ambulatory care visits, 2006-2016.
Journal of the American Pharmacists Association : JAPhA.
[DOI] 10.1016/j.japh.2021.10.020.
[PMID] 34799261.
2021
Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review.
Journal of the American Pharmacists Association : JAPhA.
61(2):e20-e44
[DOI] 10.1016/j.japh.2020.09.013.
[PMID] 33127312.
2021
Impact of Opioid Restrictions During a Critical Drug Shortage Period: Interrupted Time Series for Institutional Opioid Utilization
Pain Medicine.
22(1):203-211
[DOI] 10.1093/pm/pnaa211.
View on:
Publisher’s Site
2021
Purchasing Drugs Abroad Among U.S. Cancer Survivors: Analysis of the National Health Interview Survey, 2011-2018.
American journal of preventive medicine.
60(5):e231-e234
[DOI] 10.1016/j.amepre.2020.10.017.
[PMID] 33358718.
2021
Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015
Drug Safety.
44(4):447-454
[DOI] 10.1007/s40264-021-01053-3.
[PMID] 33683646.
2021
Trends in Use of Prescription Nonsteroidal Anti-inflammatory Medications Before vs After Implementation of a Florida Law Restricting Opioid Prescribing for Acute Pain.
JAMA network open.
4(6)
[DOI] 10.1001/jamanetworkopen.2021.13383.
[PMID] 34115125.
2020
Changes in Opioid Use After Florida’s Restriction Law for Acute Pain Prescriptions.
JAMA network open.
3(2)
[DOI] 10.1001/jamanetworkopen.2020.0234.
[PMID] 32108887.
2020
Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate
BMJ Quality & Safety.
29(8):636-644
[DOI] 10.1136/bmjqs-2019-010098.
View on:
Publisher’s Site
2020
Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries.
JAMA network open.
3(6)
[DOI] 10.1001/jamanetworkopen.2020.8968.
[PMID] 32579194.
2019
Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
76(14):1059-1070
[DOI] 10.1093/ajhp/zxz100.
[PMID] 31185072.
2018
Clinical utility and perils of prescription drug monitoring program-based alert systems.
Pain.
159(4):804-805
[DOI] 10.1097/j.pain.0000000000001157.
[PMID] 29557901.
2018
Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999-2010.
Psychiatric services (Washington, D.C.).
69(8):919-926
[DOI] 10.1176/appi.ps.201700260.
[PMID] 29879872.
2017
Acute Kidney Injury Risk Associated With Piperacillin/Tazobactam Compared With Cefepime During Vancomycin Therapy in Hospitalised Patients: a Cohort Study Stratified By Baseline Kidney Function
International Journal of Antimicrobial Agents.
50(1):63-67
[DOI] 10.1016/j.ijantimicag.2017.02.023.
View on:
Publisher’s Site
2017
Bariatric Surgery and Risk for Perinatal Complications.
JAMA surgery.
152(6):607-608
[DOI] 10.1001/jamasurg.2017.0113.
[PMID] 28329328.
2017
Consistency of psychotropic drug-drug interactions listed in drug monographs.
Journal of the American Pharmacists Association : JAPhA.
57(6):698-703.e2
[DOI] 10.1016/j.japh.2017.07.008.
[PMID] 28844584.
2017
Development and validation of a complexity score to rank hospitalized patients at risk for preventable adverse drug events.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
74(23):1970-1984
[DOI] 10.2146/ajhp160995.
[PMID] 29167139.
2017
Development and validation of a Complexity-Score to rank hospitalized patients at risk for preventable adverse drug events
American Journal of Health-System Pharmacy.
74(23):1970-1984
2017
Evaluating the effects of diffused lavender in an adult day care center for patients with dementia in an effort to decrease behavioral issues: a pilot study.
Journal of drug assessment.
6(1):1-5
[DOI] 10.1080/21556660.2016.1278545.
[PMID] 28265482.
2017
Prevalence of Psychotherapy Surrounding Initiation of Psychotropic Polypharmacy in the Medicaid-Insured Population, 1999-2010.
Psychiatric services (Washington, D.C.).
68(11):1120-1126
[DOI] 10.1176/appi.ps.201600511.
[PMID] 28669287.
2017
Use of lithium in patients with unipolar depression.
The lancet. Psychiatry.
4(9):662-663
[DOI] 10.1016/S2215-0366(17)30317-6.
[PMID] 28853406.
2014
Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.
P & T : a peer-reviewed journal for formulary management.
39(6):427-35
[PMID] 25050056.
View on:
PubMed
2012
Ototopical neomycin exposure in children with nonintact tympanic membranes.
The Laryngoscope.
122(11):2529-32
[DOI] 10.1002/lary.23554.
[PMID] 22965584.
Grants
May 2021
ACTIVE
Utilization patterns of cough medications in the United States
Role: Co-Investigator
Funding: MERCK AND COMPANY INC
Jan 2020
– Feb 2021
Leveraging social media data for evaluation of drug use trends after opioid policies
Role: Principal Investigator
Funding: AMER ASSO OF COL OF PHARMACY
Sep 2018
ACTIVE
University of Florida Resource Center for Minority Aging Research
Role: Project Manager
Funding: NATL INST OF HLTH NIA
Education
Ph.D.
2019
·
University of Florida
M.S.
2017
·
University of Florida
Pharm.D.
2013
·
University of Florida
Teaching Profile
Courses Taught
2020-2021
PHA7979 Advanced Research
2020-2021
PHA6268 Pharmacoepidemiology and Patient Safety
2020-2021
PHA6910 Supervised Research
2020-2021
PHA7980 Research for Doctoral Dissertation
2019-2021
PHA5244 Prin Evid Based Prac
2020-2021
PHA6935 Selected Topics in Pharmacy
2020-2021
PHA6971 Research for Master’s Thesis
2020
PHA5945 Leadership for International Pharmacy Outreach Experience
2020
PHA5706L Intl Outreach Exper
2018-2019
PHA5226C Pt Safety and Quality
2014-2015
PHA5742C Pro Commun Pharm Prac
2015
PHA5737 Drugs and Society
2014
PHA5226 Evidence-Base Pharmcy
2021
PHA6940 Supervised Teaching
2021
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021
PHA6937 Topics in Pharmaceutical Administration
2021
PHA6894 Introduction to Graduate Studies
Contact Details
Phones:
- Business:
- (352) 273-5526
Emails:
- Business:
- j.hincapie@ufl.edu
Recent news
Dr. Juan Hincapie-Castillo appointed to Editorial Advisory Board of the Journal of the American Pharmacists Association
Juan Hincapie-Castillo, Pharm.D., Ph.D., an assistant professor of pharmaceutical outcomes and policy in the University of Florida College of Pharmacy, has been appointed as a member of the Editorial Advisory…
Dr. Juan Hincapie-Castillo to serve in advisory role for the National Pain Advocacy Center
Dr. Hincapie-Castillo has been appointed to the Science and Policy Advisory Council for the National Pain Advocacy Center.
Drs. Lo-Ciganic and Hincapie-Castillo appointed as section co-editors for Pain Medicine journal
Pain Medicine is a multidisciplinary journal dedicated to pain clinicians, educators and researchers with an interest in pain from various medical specialties.
Dr. Juan Hincapie-Castillo appointed Research Fellow for the Temple University Center for Public Health Law Research
Hincapie-Castillo will collaborate with faculty and staff in The Center for Public Health Law Research on projects and grants in the area of legal epidemiology.